98
Views
4
CrossRef citations to date
0
Altmetric
Original Article

Treatment of patients with primary open-angle glaucoma with a fixed combination of brimonidine 0.2%/timolol 0.5%: multicenter, open-label, observational study in Germany*

, &
Pages 1003-1009 | Accepted 09 Feb 2009, Published online: 11 Mar 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Ciro Costagliola, Roberto dell'Omo, Mario R Romano, Michele Rinaldi, Lucia Zeppa & Francesco Parmeggiani. (2009) Pharmacotherapy of intraocular pressure: part I. Parasympathomimetic, sympathomimetic and sympatholytics. Expert Opinion on Pharmacotherapy 10:16, pages 2663-2677.
Read now

Articles from other publishers (3)

Anna Wójcik-Gryciuk, Małgorzata Skup & Wioletta J. Waleszczyk. (2015) Glaucoma –state of the art and perspectives on treatment. Restorative Neurology and Neuroscience 34:1, pages 107-123.
Crossref
Italo Giuffre. (2012) Comparative Evaluation of the Efficacy of the Bimatoprost 0.03%, Brimonidine 0.2%, Brinzolamide 1%, Dorzolamide 2%, and Travoprost 0.004%/Timolol 0.5%-Fixed Combinations in Patients Affected by Open-Angle Glaucoma. Open Journal of Ophthalmology 02:04, pages 122-126.
Crossref
Stella Arthur & Louis B. Cantor. (2011) Update on the role of alpha-agonists in glaucoma management. Experimental Eye Research 93:3, pages 271-283.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.